JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Начало・Списък с акции・CytoSorbents Corp

CytoSorbents Corp

Затворен

СекторЗдравеопазване

0.6

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.6

Максимум

0.62

Ключови измерители
By Trading Economics
Приходи	-2.3M -5.5M
Продажби	-251K 9.2M
Марж на печалбата	-59.526
Служители	129
EBITDA	-766K -3.7M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+22.95% upside

Дивиденти
By Dow Jones
Следващи печалби	13.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-3.9M 38M
Предишно отваряне	0.6
Предишно затваряне	0.6

Настроения в новините

By Acuity

100%

334 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

0.705 / 0.771 Подкрепа & съпротива

CytoSorbents Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.05.2026 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1.05.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1.05.2026 г., 18:37 ч. UTC

Значими двигатели на пазара

Senseonic Shares Slide on Underwritten Offering Price

1.05.2026 г., 16:46 ч. UTC

Значими двигатели на пазара

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

1.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

1.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

1.05.2026 г., 20:42 ч. UTC

Печалби

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1.05.2026 г., 19:33 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

1.05.2026 г., 19:33 ч. UTC

Пазарно говорене

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1.05.2026 г., 19:18 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1.05.2026 г., 19:13 ч. UTC

Пазарно говорене

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1.05.2026 г., 18:36 ч. UTC

Печалби

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1.05.2026 г., 18:35 ч. UTC

Печалби

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1.05.2026 г., 18:28 ч. UTC

Печалби

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1.05.2026 г., 18:27 ч. UTC

Пазарно говорене

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1.05.2026 г., 18:14 ч. UTC

Придобивния, сливания и поглъщания

Barclays Completes Acquisition of Best Egg

1.05.2026 г., 18:04 ч. UTC

Печалби

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1.05.2026 г., 17:43 ч. UTC

Пазарно говорене

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1.05.2026 г., 17:37 ч. UTC

Пазарно говорене

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1.05.2026 г., 17:30 ч. UTC

Пазарно говорене

Печалби

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1.05.2026 г., 17:28 ч. UTC

Пазарно говорене

Печалби

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1.05.2026 г., 17:21 ч. UTC

Пазарно говорене

Печалби

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1.05.2026 г., 17:19 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1.05.2026 г., 16:38 ч. UTC

Пазарно говорене

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1.05.2026 г., 16:23 ч. UTC

Придобивния, сливания и поглъщания

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

1.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

1.05.2026 г., 16:15 ч. UTC

Печалби

This AI Stock Is Up 78% This Year. Why It Still Looks Like a Buy. -- Barrons.com

1.05.2026 г., 16:11 ч. UTC

Пазарно говорене

Bank of Canada Committed a 'Messaging Blunder' -- Market Talk

1.05.2026 г., 16:04 ч. UTC

Печалби

Exxon Stock Slips. CEO Warns 'Full Impact' of War is Coming. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

CytoSorbents Corp Прогноза

Ценова цел

By TipRanks

22.95% нагоре

12-месечна прогноза

Среден 0.75 USD 22.95%

Висок 0.75 USD

Нисък 0.75 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за CytoSorbents Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на CytoSorbents Corp през последните 3 месеца.

Техническа оценка

By Trading Central

0.705 / 0.771Подкрепа & съпротива

All events are bearish.

Настроение

By Acuity

334 / 347 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.